Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20093 + adebrelimab vs docetaxel in nsq-NSCLC after platinum therapy
ChiCTR2600123594Phase 3Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of risvutatug rezetecan and adebrelimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Hunan Cancer Hospital. Primary endpoints: Progression-Free Survival (PFS) by BICR per RECIST v1.1 and Overall Survival (OS). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
risvutatug rezetecanadebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600123594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123594.